Invivyd announced positive in vitro neutralization data for its COVID-19 antibody treatment, PEMGARDA (pemivibart), against the dominant LP.8.1 variant. The company also highlighted the consistent susceptibility of prevalent variants like KP.3.1.1 and XEC to PEMGARDA, attributing this to the structural integrity of the targeted epitope. Additionally, Invivyd’s next-generation antibody candidate, VYD2311, demonstrated similar stability and neutralization against LP.8.1.
This continued effectiveness of PEMGARDA against evolving variants offers crucial protection for immunocompromised individuals who often experience limited vaccine efficacy. Consistent neutralization underscores the potential for longer-term prophylactic strategies, addressing a significant unmet need for this vulnerable population facing persistent COVID-19 risks. The stable activity also validates Invivyd’s antibody engineering approach focusing on structurally conserved viral targets.
PEMGARDA, currently authorized for pre-exposure prophylaxis in certain immunocompromised patients, maintains activity against all dominant circulating variants according to the CDC. Invivyd submitted these latest findings to the FDA, anticipating an updated fact sheet for healthcare providers. VYD2311, building upon the same structural backbone as PEMGARDA, may offer improved administration options, such as intramuscular injection.
These results suggest a promising path for Invivyd. The consistent neutralization observed with both PEMGARDA and VYD2311 reinforces the company’s strategy of targeting stable epitopes, potentially leading to durable protection against emerging COVID-19 variants and advancing the development of more accessible treatment options. This approach positions Invivyd to address ongoing challenges in managing COVID-19, particularly within vulnerable populations.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
